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ABSTRACT 
Introduction: Polycystic ovary syndrome (PCOS) women are more insulin resistant than 
general population. Prevalence data on insulin resistance (IR) in PCOS varies depending on 
population characteristics and methodology used. The objectives of this study were to 
investigate whether IR in PCOS is exclusively associated with body mass and to assess the 
prevalence of IR in lean and overweight/obese PCOS. 
Methods: Study included 250 consecutive women who attended a Department of Human 
Reproduction diagnosed as having PCOS according to the Rotterdam criteria. Control group 
comprised 500 healthy women referred for male factor infertility evaluation during the same 
period as the PCOS women. 
Results: PCOS women (n=250) were more insulin resistant than controls (n=500) even after 
adjustment for age and BMI (P=0.03). Using logistic regression analysis BMI≥25 kg/m2 (OR 
6.0; 95%CI 3.3-11.0), PCOS (OR 2.2; 95%CI 1.4-3.5) and waist circumference (WC) ≥80 cm 
(OR 2.0; 95%CI 1.1-3.8) were identified as independent determinants of IR (P<0.001). IR 
was more prevalent in overweight/obese controls (n=100) than in lean PCOS women (n=150), 
31% vs 9.3%, but less prevalent than in overweight/obese PCOS (n=100), 31% vs 57%. The 
prevalence of IR between lean controls (5%) and lean PCOS (9.3%) did not significantly 
differ.  
Conclusions: Both PCOS-specific and obesity-related IR independently contribute to IR in 
PCOS. Using HOMA-IR cut-off value of 3.15 specific for Croatian women in our clinical 
setting, the assessed prevalence of IR in lean and overweight/obese PCOS women was 9.3% 
and 57%, respectively. 
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INTRODUCTION 
The polycystic ovary syndrome (PCOS) is the most common endocrine disorder in 
reproductive age women with prevalence estimates ranging from 6% to 20% depending on 
the diagnostic criteria applied and the characteristics of population studied [1-4]. It is a very 
heterogeneous syndrome, with ethnicity, race, geographic region, and environmental factors 
contributing to both different clinical manifestation of PCOS and PCOS-associated long-term 
health risk [5]. 
Insulin resistance (IR) is typically defined as decreased sensitivity or responsiveness to the 
metabolic action of insulin [6].  IR is a prominent feature of PCOS, but it is not diagnostic 
criterion for PCOS. In addition, although insulin resistant women with PCOS are at an 
increased metabolic and cardiovascular risk, there is no general consensus on screening for IR 
in all PCOS women [5,7]. Direct, dynamic methods for measuring IR are accurate but 
inconvenient for clinical practice and epidemiological studies [6]. Among static IR indices, 
homeostasis model assessment for IR index (HOMA-IR) is the most widely used as a 
surrogate measure of IR in large population studies. However, the reports of studies 
investigating prevalence of IR in PCOS are highly inconsistent mainly due to differences in 
methods used and cut-offs selected for defining IR [8-10]. Moreover, there is an ongoing 
debate whether IR in PCOS is related to obesity alone or obesity aggravates IR intrinsic to 
PCOS [11,12]. 
Since IR in PCOS contributes to both reproductive and metabolic disturbances [6,7], it is 
clinically important to identify prevalence and degree of IR in PCOS population by using 
appropriate HOMA-IR cut-off value for identifying IR. Therefore, the objectives of this study 
were to investigate the relationship between IR and overweight/obesity in IVF patients 
diagnosed with PCOS according to the Rotterdam criteria and to derive HOMA-IR cut-off 
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value for identifying IR in our clinical setting in order to assess the prevalence and degree of 
IR in lean and overweight/obese PCOS. 
 
 
METHODS 
This cross sectional study included 250 consecutive women who attended a Department of 
Human Reproduction for infertility treatment between October 2010 and December 2012 and 
were diagnosed as having PCOS according to the Rotterdam criteria [13]. Oligomenorrhoea 
was defined as the mean menstrual cycle length >35 days in the preceding year. 
Hyperandrogenism (HA) was defined as serum testosterone concentration >2.8 nmol/L and/or 
clinically by hirsutism defined as a modified Ferriman-Gallwey (mFG) score >7 [14].  
Polycystic ovarian morphology (POM) were defined as the presence of >11 follicles 
measuring 2-9 mm in diameter in at least one ovary [15]. 
The routine laboratory tests were performed to exclude other endocrine and metabolic 
disorders. The women using medications known to have an influence that might affect 
glucose metabolism and insulin sensitivity were excluded from the study. 
Control group comprised 500 women referred to the Department of Human Reproduction for 
infertility evaluation during the same period as the PCOS women. They were randomly 
selected from the department database if met the following inclusion criteria: 1) infertility 
attributable only to male factor; 2) age≤40 years; 3) no family history of diabetes or 
hypertension; 4) regular menstrual intervals (21-35 days) in the preceding year; 5) no clinical 
or biochemical signs of hyperandrogenism; 6) normal ovarian morphology; 7) serum glucose 
concentration ≤6.0 mmol/L; 8) no previous or current, treated or not-treated, conditions that 
could interfere with study results; 9) no medications used in the past year. 
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Physical examination, blood sample collection and ultrasound assessment of ovarian 
morphology were performed on day 3-5 of a menstrual cycle or a withdrawal bleeding 
induced by gestagens [16]. 
Blood samples for the determination of glucose and hormone concentrations were taken 
between 8:00 and 9:30 hours after an overnight fast. Testosterone, follitropin (FSH) and 
lutropin (LH) concentrations were determined by chemiluminescent immunoassays on 
Access® 2 analyser (Beckman Coulter, Inc., Brea, USA). Insulin concentration was measured 
using the ADVIA Centaur® XP immunoassay system (Siemens Healthcare Diagnostics, Inc., 
Tarrytown, USA). Glucose concentration was measured using a hexokinase method 
(Beckman Coulter, Inc., Brea, USA). 
HOMA-IR was calculated using the formula: HOMA-IR=[fasting insulin (µIU/mL)xfasting 
glucose (mmol/L)]/22.5 [17]. 
AFC was assessed using a two-dimensional transvaginal probe 5-7 MHz (Toshiba, Nemio, 
Japan). 
Anthropometric measurements (height, weight, waist circumference (WC)) were performed 
on the same day as the transvaginal ultrasound scan and body mass index (BMI) was 
calculated. PCOS patients and controls were divided according to BMI in lean subgroups 
(BMI<25 kg/m2; n=150 and n=400, respectively) and overweight/obese subgroups (BMI≥25 
kg/m2; n=100 and n=100, respectively). 
For the purpose of this study the 95th percentile of distribution HOMA-IR values in lean, non-
hyperandrogenic Caucasian women with regular menstrual cycles, normal (non-polycystic) 
ovarian morphology, WC≤80 cm, and no family history of diabetes was used as cut-off value 
for identifying IR. These women (n=382) were selected from the control group. 
6 
 
As the present study is retrospective and included only analysis of data obtained from routine 
clinical and laboratory measurements, the Institutional Review Board approval was not 
required. 
 
Statistical analysis 
Data analysis was performed with MedCalc® statistical software, version 12.6.1 (MedCalc 
Software, Ostend, Belgium). The Man-Whitney test was used to test for difference between 
PCOS and control group. Analysis of covariance (ANCOVA) was used to compare HOMA-
IR values in PCOS and controls after controlling for age and BMI. The Kruskal-Wallis test 
with post-hoc pairwise comparison was used to compare the HOMA-IR in the lean and 
overweight/obese PCOS women with that of corresponding control subgroups. The chi-square 
test was used to compare the prevalence of IR in PCOS and controls before and after 
stratification in lean and overweight subgroups. The logistic regression analysis was applied 
to check for confounding effects of overweight/obesity (BMI≥25 kg/m2) and PCOS as 
dichotomous variables on IR. P value <0.05 was considered as statistically significant. 
 
RESULTS 
PCOS women were younger and had significantly higher insulin concentrations, HOMA-IR, 
WC and BMI compared with controls. Insulin and HOMA-IR remained higher in PCOS 
women than in controls even after controlling for age and BMI (Table 1). The between-group 
difference in glucose concentration was not found. As expected, obesity was more prevalent 
in PCOS than in controls (15.6% vs 4.2%; P<0.001). 
Comparison of HOMA-IR between the lean subgroups and the overweight/obese subgroups 
of controls and PCOS women after being matched for BMI is shown in Figure 1. PCOS 
women were more insulin resistant i.e. they had higher HOMA-IR than controls when the 
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lean PCOS subgroup was compared with the lean control subgroup, and when the 
overweight/obese PCOS subgroup was compared with the overweight/obese control 
subgroup, respectively (P<0.05). However, HOMA-IR was found to be significantly lower in 
lean PCOS women than in overweight/obese controls (P<0.05). 
The HOMA-IR values obtained from 382 lean (BMI<25kg/m2, WC≤80 cm) women, who 
were selected from the control group, were used for determination of cut-off value for IR. 
Their baseline characteristics are summarized in Table 2. The cut-off value for IR was defined 
as 95th percentile of the distribution of HOMA-IR observed in these lean, non-
hyperandrogenic, eumenorrhoic women of reproductive age with normal ovarian morphology 
and no family history of diabetes  i.e. IR was defined if HOMA-IR >3.15 (95%CI 2.9-3.4). 
The HOMA-IR cut-off value of 3.15 was then used to assess the prevalence of IR in IVF 
patients with PCOS. In the overall study population, there were 16.5% women with HOMA-
IR>3.15. As expected, the prevalence of IR in PCOS women was significantly higher 
(P<0.001) than in controls, 28.4% (71/250) vs 10.6% (53/500), respectively. 
After stratification of PCOS women and controls into subgroups according to BMI, the 
prevalence of IR was 5.0%, 9.3%, 31.0% and 57.0% in lean controls (n=400), lean PCOS 
women (n=150), overweight/obese controls (n=100) and overweight/obese PCOS women 
(n=100), respectively. The prevalence of IR was higher in overweight/obese controls than in 
lean PCOS women (31.0% vs 9.3%; P<0.001) but lower compared to overweight/obese 
PCOS women (31.0% vs 57.0%; P<0.001). The difference in prevalence of IR between lean 
controls (5.0%) and lean PCOS (9.3%) did not reach the level of statistical significance. 
Using logistic regression analysis, BMI≥25 kg/m2 (OR 6.0; 95%CI 3.3-11.0), PCOS (OR 2.2; 
95%CI 1.4-3.5) and WC≥80cm (OR 2.0; 95%CI 1.1-3.8) were identified as independent 
determinants of IR (P<0.001). 
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DISCUSSION 
In this study, PCOS women had higher HOMA-IR than non-PCOS women (controls) even 
after controlling for BMI and age which is indicative of decreased insulin sensitivity in PCOS 
and, thus, a higher risk for developing IR-associated metabolic disorders such as impaired 
glucose tolerance, type 2 diabetes, the metabolic syndrome and potentially cardiovascular 
disease (Table 1) [18-20]. However, no difference was found in concentration of fasting 
glucose between PCOS and controls supporting previous findings that fasting glucose could 
not serve as a sensitive indicator of IR in PCOS women. BMI and WC were also higher in 
PCOS women which corroborate previously demonstrated positive association of 
obesity/visceral adiposity with the prevalence and degree of IR [21,22]. 
Lean PCOS were more insulin resistant than BMI-matched controls but less insulin resistant 
than overweight/obese PCOS (Figure 1). These results were similar to those recently obtained 
using the clamp technique for measurement of IR [23] and support the hypothesis on the 
intrinsic, PCOS-specific IR which could be augmented by obesity-related IR [11,12]. The 
difference in IR between lean PCOS and overweight/obese controls could be explained by 
pronounced effect of body mass on IR [5]. 
Although, the prevalence of obesity (≥30 kg/m2) in Croatian woman was estimated at 20.6% 
[24], obesity is not prominent clinical feature of women admitted to our department for 
infertility treatment. Only 8.0% women in this study cohort were obese. The prevalence of 
obesity in PCOS group was also very low (15.6%) compared with reported prevalence of 
obese women in studies conducted in the U.S. and Australia. In these countries, 61% and 76% 
PCOS women were considered obese [5]. The observed between-studies differences in 
prevalence of overweight/obese women are reflection of geographic location, ethnicity, 
environmental factors (lifestyle, diet) and criteria used for diagnosing PCOS.  
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It is clinically important to identify insulin resistant women in infertile IVF population in 
order to reduce their long-term metabolic risk and/or improve reproductive outcomes through 
lifestyle changes and pharmacological interventions [5,25]. Insulin promotes primordial to 
primary follicle transition [26]. In addition, FSH-responsiveness of granulosa cells of 
gonadotropin-dependent stages of folliculogenesis are enhanced by insulin growth factors 
[27]. Therefore, in the IVF setting, the multifolliculogenesis as an response to exogenous 
gonadotropin stimulation is more frequent in insulin resistant patients who are, thus, more 
prone to develop ovarian hyperstimulation syndrome [28,29]. The identification of insulin 
resistant patients prior to the IVF procedure could help clinicians to decrease the risk of IVF 
complications by choosing appropriate ovarian stimulation protocol and optimal gonadotropin 
dose and/or to assess potential benefit from insulin-sensitizing therapy. 
In this study, the 95th percentile of HOMA-IR in healthy, lean women was selected as the 
optimal cut-off for distinguishing insulin resistant from insulin sensitive individuals. Recent 
study using pre-selected HOMA-IR cut-off ≥2.5 identified 22.6% non-obese PCOS women as 
being insulin resistant while the overall prevalence of IR was estimated at 31.6% in the 
similar sample of women with PCOS [17,30]. If the same cut-off has been selected as 
criterion in this study, more than 10% of healthy lean controls with WC<80 cm would be 
identified as being IR. Therefore, the use of pre-selected HOMA-IR cut-off for identifying 
those with IR should be discouraged since, even in the ethnically homogeneous population, 
substantial differences in HOMA-IR cut-off value used could have an influence on 
identification of insulin resistant women and therefore, their healthcare management [9,31].  
Thus, IR was defined as HOMA-IR>3.15. The observed prevalence of IR in PCOS was 
28.4% and significantly higher compared with controls (10.6%), but lower compared with 
other reports (44-70%) [6,32]. The prevalence of IR was similar in lean controls and lean 
PCOS but higher in overweight PCOS compared with overweight controls. Nevertheless, an 
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independent association of overweight/obesity (BMI≥25 kg/m2), PCOS (the Rotterdam 
criteria) and abdominal obesity (WC≥80 cm) with IR demonstrated in this study corroborates 
the role of intrinsic, PCOS-specific IR [6,11,12]. 
The limitation of this study is concern about sensitivity and accuracy of HOMA-IR to assess 
IR compared with the gold standard technique for measuring IR. However, due to 
convenience and cost-saving, HOMA-IR is considered appropriate for large scale and 
epidemiological studies with cross-sectional design [33]. The fact that control group included 
women undergoing IVF could be recognized as one of the study limitation. However, all 
women from the control group underwent IVF treatment due to the male factor infertility and 
not any other infertility issue, whatsoever. Controls could therefore be considered as 
representatives of the general population or a true control group although included patients 
referred to the Department of Human Reproduction for infertility treatment. Moreover, all 
women from the control group underwent transvaginal ultrasound examination and those with 
polycystic ovaries were not included in the control group of the study. 
The main advantages of this study were homogeneity of study population with respect to 
racial, ethnic, and geographic origin and absence of selection bias other than being evaluated 
for infertility treatment. Furthermore, the ultrasound ovarian examination and the assessment 
of hirsutism were performed by the same physician, thus eliminating interobserver bias. 
In conclusion, the prevalence of IR, as defined by HOMA-IR>3.15, was 28.4% in infertile 
Croatian women with PCOS. The prevalence of IR in lean and overweight/obese PCOS was 
9.3% and 57%, respectively. Both PCOS-specific and obesity-related IR independently 
contribute to IR in PCOS. These study results support the necessity of determination of the 
clinical setting-specific HOMA-IR cut-off value for identifying IR for routine clinical practice 
and in studies aimed to investigate IR prevalence. Accordingly, the HOMA-IR cut-off value 
used in our clinical setting could not be advised to be applied universally. 
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Table 1. Baseline characteristics of study population 
 
Variable Controls (n=500) PCOS women (n=250) P P* 
Age (years) 33.1 (30.4 - 36.0) 29.9 (27.4 - 32.5) <0.001 NA 
BMI (kg/m2) 23 (21 - 25) 24 (21 - 29) <0.001 NA 
Waist circumference 
(cm) 
70 (66 - 78) 76 (68 - 87) <0.001 0,103 
Testosterone (nmol/L) 1.4 (1.0 -1.8) 2.0 (1.5 - 2.7) <0.001 <0.001 
mFG score 2 (1 - 2) 6 (3 - 10) <0.001 <0.001 
FSH (IU/L) 7.4 (6.2 - 9.1) 6.0 (4.9 - 7.4) <0.001 <0.001 
LH (IU/L) 4.5 (3.5 - 5.9) 6.0 (4.1 - 8.6) <0.001 <0.001 
Glucose (mmol/L) 5.2 (5.0 - 5.5) 5.2 (4.9 - 5.5) 0.241 0,112 
Insulin (mIU/L) 6.9 (5.3 - 9.0) 9.7 (6.5 - 14.6) <0.001 0,011 
HOMA-IR 1.6 (1.1 - 2.1) 2.3 (1.5 - 3.4) <0.001 0,023 
     
Values are median (interquartile range). NA = not applicable; mFG score = modified Ferriman Gallwey score.  
P - value was assessed using Mann-Whitney test; P - value* was assessed using ANCOVA after controlling for 
age and BMI; P < 0.05 was considered statistically significant. 
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Table 2. Baseline characteristics of lean controls (BMI < 25 kg/m2, waist circumference < 80 
cm) selected to determine the clinical setting-specific HOMA-IR cut-off value for 
identification of insulin resistance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are median (interquartile range). 
 
 
 
 
 
Variable Lean controls (n=382) 
Age (years) 33.3 (30.3 - 36.0) 
BMI (kg/m2) 22 (20 - 24) 
Waist circumference (cm) 69 (65 - 73) 
Menstrual cycle length (days) 29 (28 - 30) 
Modified  Ferriman-Gallwey score 2 (1 - 2) 
Antral follicle count 12 (8 - 15) 
Testosterone (nmol/L) 1.4 (1.0 - 1.7) 
FSH (IU/L) 7.6 (6.2 - 9.4) 
LH (IU/L) 4.6 (3.6 - 6.1) 
Insulin (mIU/L) 6.9 (5.3 - 9.0) 
Glucose (mmol/L) 5.2 (5.0 - 5.5) 
HOMA-IR 1.5 (1.2 - 2.1) 
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Figure 1: Comparison of HOMA-IR in BMI-matched PCOS women and controls 
 
 
 
L-CTRL - lean (BMI < 25 kg/m2) controls (n=400); L-PCOS - lean PCOS (n=150); OW-CTRL - 
overweight/obese (BMI ≥ 25 kg/m2) controls (n=100); OW-PCOS - overweight/obese PCOS (n=100). 
Middle horizontal lines represent the medians. Horizontal small bars indicate 27-75th percentile range. 
P - value was calculated by Kruskal-Wallis test with pairwise between-group comparison 
according to Conover. The P - value  <0.05 was considered as statistically significant (a  - 
denotes the significant difference compared with L-CTRL,  b - denotes the significant 
difference compared with L-PCOS, c - denotes the significant difference compared with OW-
CTRL and d - denotes the significant difference compared with OW-PCOS) 
